MedTrace Logo

Role of the Immune Environment in Response to Therapy in Breast Cancer

NCT05396612 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2025-07-08

No results posted yet for this study

Summary

This is an observational case-control study of tissues collected from women with ER+HER2- breast cancers. The immune environments of these cancers will be compared to triple negative and HER2+ breast cancers. No randomization or changes to standard of care treatment will occur as part of the study.

Conditions

Interventions

OTHER

Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.

Collection of personal health information from women treated at the University of Pennsylvania under an approved HIPAA waiver.

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Jennifer Zhang, MD · Abramson Cancer Center

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-03
Primary Completion
2032-12-31
Completion
2032-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05396612 on ClinicalTrials.gov